Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash from Operations: 2021-2025

Historic Cash from Operations for InMed Pharmaceuticals (INM) over the last 5 years, with Sep 2025 value amounting to -$1.6 million.

  • InMed Pharmaceuticals' Cash from Operations rose 12.00% to -$1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.5 million, marking a year-over-year decrease of 13.70%. This contributed to the annual value of -$7.8 million for FY2025, which is 11.18% down from last year.
  • InMed Pharmaceuticals' Cash from Operations amounted to -$1.6 million in Q3 2025, which was up 9.61% from -$1.8 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Cash from Operations ranged from a high of -$657,934 in Q2 2023 and a low of -$5.3 million during Q1 2022.
  • In the last 3 years, InMed Pharmaceuticals' Cash from Operations had a median value of -$1.8 million in 2025 and averaged -$1.7 million.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Cash from Operations skyrocketed by 83.74% in 2023, and later plummeted by 72.81% in 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Cash from Operations (MRQ) stood at -$3.5 million in 2021, then increased by 23.22% to -$2.7 million in 2022, then surged by 31.88% to -$1.8 million in 2023, then crashed by 35.39% to -$2.5 million in 2024, then skyrocketed by 35.75% to -$1.6 million in 2025.
  • Its Cash from Operations stands at -$1.6 million for Q3 2025, versus -$1.8 million for Q2 2025 and -$1.7 million for Q1 2025.